Procaine Composite for SARS-CoV-2 Entry Disruption and Tumor Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for pharmaceutical compositions that can disrupt the interaction between the SARS-CoV-2 virus and host cell ACE2 receptors to treat or prevent coronavirus infections, and compositions that can inhibit the growth of adenocarcinomas and promote cytoreduction of tumors.

Innovation Solution

A composition comprising procaine, a tri- or tetra-peptide with glutamate residues, DNase 1, and optionally RNase A, which can be administered to enhance oxygen delivery to tissues and inhibit tumor growth, reduce viral infection symptoms, and promote cytoreduction of adenocarcinomas.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (surgery, radiation, chemotherapy) are used for adenocarcinoma, then tumor removal or growth inhibition is achieved, but patient quality of life deteriorates and treatment resistance develops

Engineering Contradiction:

Improvetumor treatment effectivenessVSAvoidpatient quality of life and treatment resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses a composite formulation containing multiple active ingredients (procaine, glutathione, DNase 1, RNase A) in specific concentrations. This composite approach combines agents with different mechanisms of action - procaine for membrane disruption and oxygen delivery enhancement, glutathione for antioxidant protection and viral entry inhibition, DNase 1 for DNA damage induction, and RNase A for RNA degradation - creating a synergistic effect that overcomes treatment resistance while reducing harmful side effects compared to single-agent chemotherapy

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent employs parameter changes by delivering the composition under controlled conditions (intravenous injection, intratumoral injection, or inhalation) with specific dosage regimens. The formulation includes procaine at 0.1-1.0% to enhance oxygen delivery and disrupt viral entry, glutathione at 1-10% for antioxidant activity and ACE2 receptor competition, DNase 1 at 0.001-0.1% for DNA damage, and RNase A at 0.01-1.0% for RNA degradation. These parameter optimizations enable effective tumor growth inhibition and viral entry disruption while minimizing tissue damage and maintaining patient quality of life

Inventive Principle:

Principle #35Parameter changes

2Reliability

If SARS-CoV-2 viral load increases, then respiratory symptoms worsen and lung damage increases, but oxygen delivery to tissues decreases

Engineering Contradiction:

Improveviral infection treatment effectivenessVSAvoidoxygen delivery to tissues

Core Design Contradiction:

ReliabilityVSUse of energy by moving object

Solution Approach 1:

The patent uses procaine as an intermediary substance that enhances oxygen delivery to tissues infected with SARS-CoV-2. Procaine acts as a mediator by disrupting viral entry into host cells through interaction with the viral envelope or membrane, thereby improving oxygenation without directly attacking the virus. This intermediary approach allows oxygen to reach hypoxic tissues while simultaneously reducing viral load, resolving the contradiction between treating viral infection and maintaining oxygen delivery

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The composite formulation combines procaine (0.1-1.0%) for oxygen delivery enhancement and viral entry disruption, glutathione (1-10%) for antioxidant protection against viral-induced oxidative stress and ACE2 receptor competition, DNase 1 (0.001-0.1%) for viral DNA degradation, and RNase A (0.01-1.0%) for viral RNA degradation. This multi-component system simultaneously addresses viral replication inhibition and oxygen delivery improvement, treating respiratory symptoms while enhancing tissue oxygenation

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively disrupts viral entry into host cells, enhances oxygen delivery, and inhibits tumor growth, reducing lung damage from COVID-19 and shrinking adenocarcinomas.

Implementation Method 1

The composition effectively disrupts viral entry into host cells

Methodology Applied

Scientific EffectViral entry disruption:

Implementation Method 2

DNase 1 or a pharmaceutically acceptable salt thereof

Methodology Applied

Scientific EffectDNA degradation: Enzyme

Implementation Method 3

RNase A, or a pharmaceutically acceptable salt thereof

Methodology Applied

Scientific EffectRNA degradation: Enzyme

Implementation Method 4

Pharmaceutical compositions are needed that can disrupt the interaction between the SARS-CoV-2 virus and host cell

Methodology Applied

Scientific EffectReceptor binding disruption:

Implementation Method 5

The composition inhibits the growth of tumor cells and promotes cytoreduction of tumors

Methodology Applied

Scientific EffectTumor cell inhibition:

Data Source

PatentUS20250332136A1Composition and methods for treatment or prophylaxis of coronavirus and cancers

Publication Date: 2025.10.30 BETAHEALTH LLC

AI summary

Described herein is a composition and methods for treating, reducing the symptoms of, or prophylaxis of viral infections, and particularly SARS-CoV-2. The composition enhances delivery of oxygen to the tissues. Also described herein is a composition and methods for treating cancers, particularly, adenocarcinomas, infiltrating ductal adenocarcinoma, metastatic ductal adenocarcinoma, and neuroendocrine tumors. The composition inhibits the growth of tumor cells and promotes cytoreduction of tumors.